ITCI: Intra-Cellular Therapies is a biopharmaceutical company focused on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, behavioral disturbances in dementia, bipolar disorder and other neuropsychiatric and neurological disorders. The Company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of several neuropsychiatric and neurodegenerative diseases. The lead compound in this platform, ITI-214, has finished several Phase 1 clinical trials and has been demonstrated to be safe and well-tolerated. In addition, the Company is developing inhibitors against other targets for CNS indications such as Alzheimer's disease, Parkinson's disease and depression and non-CNS indications such as pulmonary arterial hypertension, multiple sclerosis, COPD and lung fibrosis.